Market research
300529.SHE Jafron Biomedical Co.,Ltd
SHE CNY Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 12B
- P/E ratio
- 22.64
- Analyst target
- 24.115
- Dividend yield
- 3.4%
- Beta
- 0.31
Community
Investor discussion
1 comment
Sign in to join the 300529.SHE discussion.
5 years, 5 months ago
Jafron Biomedical Co.,Ltd is currently in a long term uptrend where the price is trading 4.7% above its 200 day moving average.
From a valuation standpoint, the stock is 264.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 35.1.
Jafron Biomedical Co.,Ltd's total revenue rose by 38.0% to $635M since the same quarter in the previous year.
Its net income has increased by 62.1% to $248M since the same quarter in the previous year.
Finally, its free cash flow grew by 99.4% to $320M since the same quarter in the previous year.
Based on the above factors, Jafron Biomedical Co.,Ltd gets an overall score of 4/5.